These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 24815381

  • 1. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
    Carozzi F, De Marco L, Gillio-Tos A, Del Mistro A, Girlando S, Baboci L, Trevisan M, Burroni E, Grasso S, Giorgi Rossi P, Ronco G, NTCC Working Group.
    J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
    [Abstract] [Full Text] [Related]

  • 2. HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program.
    Tabrizi SN, Brotherton JM, Stevens MP, Condon JR, McIntyre P, Smith D, Garland SM, WHINURS group.
    J Clin Virol; 2014 Jul; 60(3):250-6. PubMed ID: 24854516
    [Abstract] [Full Text] [Related]

  • 3. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention?
    Kjær SK, Munk C, Junge J, Iftner T.
    Cancer Causes Control; 2014 Feb; 25(2):179-89. PubMed ID: 24242002
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J, Zerat L, Syrjänen K, Zerat JC, Smith JS, Halfon P.
    Vaccine; 2012 Jul 27; 30(35):5215-21. PubMed ID: 22713720
    [Abstract] [Full Text] [Related]

  • 5. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
    Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE.
    J Natl Cancer Inst; 2009 Apr 01; 101(7):475-87. PubMed ID: 19318628
    [Abstract] [Full Text] [Related]

  • 6. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F, Puliti D, Ocello C, Anastasio PS, Moliterni EA, Perinetti E, Serradell L, Burroni E, Confortini M, Mantellini P, Zappa M, Dominiak-Felden G.
    BMC Infect Dis; 2018 Jan 15; 18(1):38. PubMed ID: 29334901
    [Abstract] [Full Text] [Related]

  • 7. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
    Arbyn M, Benoy I, Simoens C, Bogers J, Beutels P, Depuydt C.
    Cancer Epidemiol Biomarkers Prev; 2009 Jan 15; 18(1):321-30. PubMed ID: 19124515
    [Abstract] [Full Text] [Related]

  • 8. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM, Cornall AM, Brotherton JML, Wark JD, Malloy MJ, Tabrizi SN, VACCINE study group.
    Vaccine; 2018 May 31; 36(23):3221-3230. PubMed ID: 29724506
    [Abstract] [Full Text] [Related]

  • 9. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjänen S, Poljak M.
    Vaccine; 2013 Dec 31; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [Abstract] [Full Text] [Related]

  • 10. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A.
    Lancet; 2009 Jun 06; 373(9679):1949-57. PubMed ID: 19493565
    [Abstract] [Full Text] [Related]

  • 11. Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy.
    Agarossi A, Ferrazzi E, Parazzini F, Perno CF, Ghisoni L.
    J Med Virol; 2009 Mar 06; 81(3):529-35. PubMed ID: 19152401
    [Abstract] [Full Text] [Related]

  • 12. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study.
    Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurjargal D, Avirmed D, Enkhtuya S, Kommoss F, Wentzensen N, Snijders PJ, Meijer CJ, Franceschi S, Pawlita M.
    Cancer Epidemiol Biomarkers Prev; 2008 Jul 06; 17(7):1731-8. PubMed ID: 18628425
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study.
    Castellsagué X, Iftner T, Roura E, Vidart JA, Kjaer SK, Bosch FX, Muñoz N, Palacios S, San Martin Rodriguez M, Serradell L, Torcel-Pagnon L, Cortes J, CLEOPATRE Spain Study Group.
    J Med Virol; 2012 Jun 06; 84(6):947-56. PubMed ID: 22499018
    [Abstract] [Full Text] [Related]

  • 14. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.
    Mesher D, Panwar K, Thomas SL, Beddows S, Soldan K.
    BMJ Open; 2016 Feb 11; 6(2):e009915. PubMed ID: 26868944
    [Abstract] [Full Text] [Related]

  • 15. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M, Dillner J.
    J Clin Virol; 2007 Mar 11; 38(3):189-97. PubMed ID: 17258503
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of human papillomavirus in young Italian women with normal cytology: how should we adapt the national vaccination policy?
    Panatto D, Amicizia D, Tanzi E, Bianchi S, Frati ER, Zotti CM, Lai PL, Bechini A, Rossi S, Gasparini R.
    BMC Infect Dis; 2013 Dec 06; 13():575. PubMed ID: 24313984
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and distribution of human papillomavirus genotype in south eastern Italy, in the period 2006-2011: implications for intervention.
    Guido M, Tinelli A, De Donno A, Bruno AR, Tagliaferro L, Fedele A, Carbone A, Menegazzi P, Aprile V, Greco M, Malvasi A, Piccinni MA, Turano S, Grima P, Dell' Ederam D, Zizza A.
    Curr Pharm Des; 2013 Dec 06; 19(8):1498-507. PubMed ID: 23016783
    [Abstract] [Full Text] [Related]

  • 18. Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: a cervical cancer screening based study.
    Učakar V, Poljak M, Klavs I.
    Vaccine; 2012 Jan 05; 30(2):116-20. PubMed ID: 22080175
    [Abstract] [Full Text] [Related]

  • 19. Prevalence of human papillomavirus (HPV) types in cervical cancer 2003-2008 in Stockholm, Sweden, before public HPV vaccination.
    Du J, Näsman A, Carlson JW, Ramqvist T, Dalianis T.
    Acta Oncol; 2011 Nov 05; 50(8):1215-9. PubMed ID: 21726177
    [Abstract] [Full Text] [Related]

  • 20. Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention.
    Alemany L, Pérez C, Tous S, Llombart-Bosch A, Lloveras B, Lerma E, Guarch R, Andújar M, Pelayo A, Alejo M, Ordi J, Klaustermeier J, Velasco J, Guimerà N, Clavero O, Castellsagué X, Quint W, Muñoz N, Bosch FX, de Sanjosé S, Spanish study group RIS HPV TT.
    Gynecol Oncol; 2012 Mar 05; 124(3):512-7. PubMed ID: 22119990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.